Free Trial

Capricor Therapeutics (CAPR) Competitors

Capricor Therapeutics logo
$7.06 +0.58 (+8.95%)
Closing price 04:00 PM Eastern
Extended Trading
$7.00 -0.06 (-0.79%)
As of 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CAPR vs. NTLA, WVE, PHVS, CVAC, CDTX, PAHC, CALT, AUPH, ELVN, and GPCR

Should you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Intellia Therapeutics (NTLA), WAVE Life Sciences (WVE), Pharvaris (PHVS), CureVac (CVAC), Cidara Therapeutics (CDTX), Phibro Animal Health (PAHC), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

Capricor Therapeutics vs. Its Competitors

Capricor Therapeutics (NASDAQ:CAPR) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Capricor Therapeutics has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500.

Capricor Therapeutics has a net margin of -181.71% compared to Intellia Therapeutics' net margin of -1,154.10%. Intellia Therapeutics' return on equity of -56.06% beat Capricor Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Capricor Therapeutics-181.71% -62.42% -48.36%
Intellia Therapeutics -1,154.10%-56.06%-44.25%

21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 10.5% of Capricor Therapeutics shares are owned by insiders. Comparatively, 3.1% of Intellia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Capricor Therapeutics presently has a consensus target price of $22.56, indicating a potential upside of 219.48%. Intellia Therapeutics has a consensus target price of $33.37, indicating a potential upside of 145.36%. Given Capricor Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Capricor Therapeutics is more favorable than Intellia Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capricor Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11
Intellia Therapeutics
1 Sell rating(s)
6 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.65

Capricor Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capricor Therapeutics$17.36M18.57-$40.47M-$1.42-4.97
Intellia Therapeutics$45.57M30.91-$519.02M-$5.23-2.60

In the previous week, Capricor Therapeutics had 14 more articles in the media than Intellia Therapeutics. MarketBeat recorded 24 mentions for Capricor Therapeutics and 10 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.92 beat Capricor Therapeutics' score of -0.06 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Capricor Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
22 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Intellia Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Intellia Therapeutics beats Capricor Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Capricor Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CAPR vs. The Competition

MetricCapricor TherapeuticsMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$322.48M$10.42B$5.74B$9.51B
Dividend YieldN/A2.00%4.60%3.99%
P/E Ratio-4.9717.0728.1120.03
Price / Sales18.5728.05460.63103.88
Price / CashN/A23.2136.5559.01
Price / Book2.213.698.655.90
Net Income-$40.47M$234.77M$3.25B$258.66M
7 Day Performance2.62%6.33%4.20%2.23%
1 Month Performance-29.75%8.39%10.83%12.77%
1 Year Performance59.37%-13.50%34.67%19.36%

Capricor Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CAPR
Capricor Therapeutics
2.5395 of 5 stars
$7.06
+9.0%
$22.56
+219.5%
+42.4%$322.48M$17.36M-4.97101
NTLA
Intellia Therapeutics
4.5172 of 5 stars
$12.63
+4.7%
$33.37
+164.2%
-50.1%$1.25B$57.88M0.00600News Coverage
Insider Trade
High Trading Volume
WVE
WAVE Life Sciences
4.5582 of 5 stars
$7.87
-5.6%
$20.15
+156.1%
+36.4%$1.22B$108.30M-9.37240Positive News
Upcoming Earnings
PHVS
Pharvaris
1.44 of 5 stars
$23.84
+2.5%
$36.20
+51.8%
+12.3%$1.22BN/A0.0030News Coverage
CVAC
CureVac
4.7508 of 5 stars
$5.40
+0.2%
$6.83
+26.5%
+51.1%$1.21B$579.18M5.86880Positive News
CDTX
Cidara Therapeutics
3.4892 of 5 stars
$57.05
-4.9%
$57.29
+0.4%
+430.1%$1.21B$1.27M0.0090High Trading Volume
PAHC
Phibro Animal Health
4.0871 of 5 stars
$29.14
-0.9%
$24.40
-16.3%
+56.7%$1.19B$1.02B15.241,940Positive News
CALT
Calliditas Therapeutics AB (publ)
N/A$40.00
flat
N/AN/A$1.19B$1.60B-21.62180
AUPH
Aurinia Pharmaceuticals
2.9982 of 5 stars
$8.62
-0.1%
$11.50
+33.4%
+63.1%$1.17B$235.13M23.32300Upcoming Earnings
ELVN
Enliven Therapeutics
2.6313 of 5 stars
$21.87
-3.5%
$41.20
+88.4%
-8.6%$1.11BN/A0.0050Insider Trade
GPCR
Structure Therapeutics
2.952 of 5 stars
$18.13
-5.8%
$76.17
+320.1%
-49.6%$1.10BN/A0.00136Positive News

Related Companies and Tools


This page (NASDAQ:CAPR) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners